CoChat
Sign Up
Cited by 1,172Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchAmyloidosis: Diagnosis, Treatment, Outcomes

Prognostic factors in ALS: A critical review

Open access
Chiò, Adriano, Logroscino, Giancarlo, Hardiman, Orla, Swingler, Robert, Mitchell, Douglas, Beghi, Ettore, Traynor, Bryan G., On Behalf of the Eurals Consortium·2009·Amyotrophic Lateral Sclerosis
DOI 10.3109/17482960802566824PMC PMC3515205
Open this paper in CoChat — free account

Abstract

We have performed a systematic review to summarize current knowledge concerning factors related to survival in ALS and to evaluate the implications of these data for clinical trials design. The median survival time from onset to death ranges from 20 to 48 months, but 10-20% of ALS patients have a survival longer than 10 years. Older age and bulbar onset are consistently reported to have a worse outcome. There are conflicting data on gender, diagnostic delay and El Escorial criteria. The rate of symptom progression was revealed to be an independent prognostic factor. Psychosocial factors, FTD, nutritional status, and respiratory function are also related to ALS outcome. The effect of enteral nutrition on survival is still unclear, while NIPPV has been found to improve survival. There are no well established biological markers of progression, although some are likely to emerge in the near future. These findings have relevant implications for the design of future trials. Randomization, besides the type of onset, should take into account age, respiratory status at entry, and a measure of disease progression pre-entry. Alternative trial designs can include the use of natural history controls, the so-called minimization method for treatment allocation, and the futility approach.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/17482960802566824

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bulbar onset ALS has been associated with faster disease progression.

    “Although bulbar onset ALS has been associated with faster disease progression (44), DFS rates were not significantly different between participants with ALSþCTE and ALS only although this analysis is likely underpowered due to the small number of participants with CTE.”

    From Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort (2018) · cites this paper as [44]

    The Site of onset section says bulbar-onset ALS is associated with a worse prognosis than spinal-onset ALS. The review discusses progression rates separately, but does not establish that bulbar onset itself is associated with faster disease progression. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 101

  1. [2]Albert SM Murphy PL Del Bene ML Rowland LP A prospective study of preferences and actual treatment choices in ALS Neurology 1999 53 278 83 10430414
  2. [3]Miller RG Munsat TL Swash M Brooks BR for the World Federation of Neurology Committee on Research Consensus guidelines for the design and implementation of clinical trials in ALS J Neurol Sci 1999 169 2 12 10540001
  3. [4]Borasio GD Amyotrophic lateral sclerosis: lessons in trial design from recent trials J Neurol Sci 1997 152 Suppl 1 S23 8 9419050
  4. [5]Lai EC Flice KJ Festoff BW Gawel MJ Gelinas DF Kratz R the North America ALS/IGF-I Study Group Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo controlled study Neurology 1997 49 1621 30 9409357
  5. [6]Borasio GD Robberecht W Leigh PN Emile J Guiloff RJ Jerusalem F European ALS/IGF-I Study Group A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis Neurology 1998 51 583 6 9710040
  6. [7]Italian ALS Study Group Branched chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993 43 2466 70 8255440
  7. [8]Norris F Sheperd R Denys E U K Mukai E Elias L Holden D Norris H Onset, natural history and outcome in idiopathic adult motor neuron disease J Neurol Sci 1993 118 48 55 8229050
  8. [10]Haverkamp LJ Appel V Appel SH Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction Brain 1995 118 707 19 7600088
  9. [11]Preux P-M Couratier P Boutros-Toni F Salle J-Y Tarabaud F Bernet-Bernady P Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors Neuroepidemiology 1996 15 153 60 8700307
  10. [12]Louwerse ES Visser CE Bossuyt PMM Weverling GJ the Netherlands ALS Consortium Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors J Neurol Sci 1997 152 Suppl 1 S10 7 9419048
  11. [13]Turner MR Bakker M Sham P Shaw CE Leigh PN AlChalabi A Prognostic modelling of therapeutic interventions amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis 2002 3 15 21 12061944
  12. [14]Testa D Lovati R Ferrarini M Salmoiraghi F Filippini G Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period Amyotrophic Lateral Sclerosis 2004 5 208 12 15799548
  13. [15]Paillisse C Lacomblez L Dib M Bensimon G GarciaAcosta S Meininger V Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole Amyotrophic Lateral Sclerosis 2005 6 37 44 16036424
  14. [16]Stambler N Charatan M Cedarbaum JM ALS CNTF Treatment Study Group Prognostic indicators of survival in ALS Neurology 1998 50 66 72 9443459
  15. [17]Lee JR Annegers JF Appel SH Prognosis of amyotrophic lateral sclerosis and the effect of referral selection Lett Neurol Sci 1995 132 207 15 8543950
  16. [18]Brooks BR Miller RG Swash M Munsat TL World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis Amyotroph Lateral Scler Other Motor Neuron Disord 2000 1 293 9 11464847
  17. [19]Yoshida S Mulder DW Kurland LT Chu C-P Okazaki H Follow-up study on amyotrophic lateral sclerosis in Rochester, Minnesota 1925 through 1984 Neuroepidemiology 1986 5 61 70 3785524
  18. [20]Christensen PB Hoier-Pedersen E Jensen BN Survival of patients with amyotrophic lateral sclerosis in two Danish counties Neurology 1990 40 600 4 2320232
  19. [21]Tysnes O-B Vollset SE Larsen JP Aarli JA Prognostic factors and survival in amyotrophic lateral sclerosis Neuroepidemiology 1994 13 226 35 7969707
  20. [22]Sorenson EJ Stalker AP Kurland LT Windebank AJ Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998 Neurology 2002 59 280 2 12136072
  21. [23]Chancellor AM Slattery JM Frazer H Swingler RJ Holloway SM Wallow CP The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register J Neurol 1993 240 339 46 8336173
  22. [24]Traynor BJ Codd BM Corr B Forde C Frost E Hardiman O Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria Arch Neurol 2000 57 1171 6 10927797
  23. [25]Chiò A Mora G Leone M Mazzini L Cocito D Giordana MT for the Piemonte and Valle d’Aosta Register for ALS. Early symptom progression rate is related to ALS outcome: a prospective population-based study Neurology 2002 59 99 103 12105314
  24. [26]del Aguila MA Longstreth WT Jr McGuire V Koepsell TD van Belle G Prognosis in amyotrophic lateral sclerosis. A population-based study Neurology 2003 60 813 9 12629239
  25. [27]Millul A Beghi E Logroscino G Micheli A Vitelli E Zardi A Survival of patients with amyotrophic lateral sclerosis in a population-based registry Neuroepidemiology 2005 25 114 9 15956808
  26. [28]Armon C Moses D Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials J Neurol Sci 1998 160 Suppl 1 S37 41 9851647
  27. [29]Czaplinski A Yen AA Appel SH Amyotrophic lateral sclerosis: early predictors of prolonged survival J Neurol 2006 253 1428 36 16773270
  28. [30]Forbes RB Colville S Cran GW Swingler RJ Unexpected decline in survival from amyotrophic lateral sclerosis/motor neuron disease J Neurol Neurosurg Psychiatry 2004 75 1753 5 15548498 PMC1738850
  29. [31]Forbes RB Colville S Swingler RJ for the Scottish ALS/MND Register The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 years or above Age Ageing 2004 33 131 4 14960427
  30. [33]Lopez-Vega JM Calleja J Combarros O Polo JM Berciano J Motor neuron disease in Cantabria Acta Neurol Scand 1988 77 1 5 3354306
  31. [34]Marti-Fabregas J Fredas J Illa I Prognostic factors in amyotrophic lateral sclerosis Neurologia 1996 11 174 81 8754633
  32. [35]Tysnes O-B Vollset SE Aarli JA Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway Acta Neurol Scand 1991 83 280 5 2063649
  33. [36]Bourke SC Tomlison M Wlliams TL Bullock RE Shaw PJ Gibson GJ Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial Lancet Neurology 2006 5 140 7 16426990
  34. [37]de Carvalho M Matias T Coelho F Evangelista T Pinto A Lùis ML Motor neuron disease presenting with respiratory failure J Neurol Sci 1996 139 Suppl 117 22 8899670
  35. [38]Shoesmith CL Findlater K Rowe A Strong MJ Prognosis of amyotrophic lateral sclerosis with respiratory onset J Neurol Neurosurg Psychiatr 2007 78 629 31 17088331 PMC2077959
  36. [39]Magnus T Beck M Giess R Naumann M Toyka KV Disease progression in amyotrophic lateral sclerosis: predictors of survival Muscle Nerve 2002 25 709 14 11994965
  37. [40]Thijs V Peeters E Theys P Matthijs G Robberecht W Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population Acta Neurol Belg 2000 100 84 90 10934559
  38. [41]Kaufmann P Levy G Thompson JL Delbene ML Battista V Gordon PH The ALSFRS-R predicts survival time in an ALS clinic population Neurology 2005 64 38 43 15642901
  39. [42]Beghi E Millul A Logroscino G Vitelli E Micheli A SLALOM GROUP Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis Amyotroph Lateral Scler 2008 9 163 7 18574760
  40. [43]Cudkowicz ME McKenna-Yasek D Sapp PE Chin W Geller B Hayden DL Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis Ann Neurol 1997 41 210 21 9029070
  41. [44]Aggarwal A Nicholson G Age-dependent penetrance of three different superoxide dismutase 1 (SOD1) mutations Int J Neurosci 2005 115 1119 30 16040355
  42. [45]Juneja T Pericak-Vance MA Laing NG Dave S Siddique T Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu/Zn superoxide dismutase Neurology 1997 48 55 7 9008494
  43. [46]Andersen PM Amyotrophic lateral sclerosis associated with mutations in the Cu/Zn superoxide dismutase gene Curr Neurol Neurosci Reports 2006 6 36 47 16469270
  44. [47]Armon C Graves MC Moses D Forte DK Sepulveda L Darby SM Smith RA Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis Muscle Nerve 2000 23 874 82 10842262
  45. [48]Bryan WW Hoagland RJ Murphy J Armon C Barohn RJ Goodpasture JC the rhCNTF ALS Study Group Can we eliminate placebo in Amyotrophic Lateral Sclerosis clinical trials? Amyotrophic Lateral Sclerosis 2002 4 11 5 12745612
  46. [49]Kimura F Fujimura C Ishida S Nakajima H Furutama D Uehara H Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS Neurology 2006 66 265 7 16434671
  47. [51]Armon C Brandstater ME Motor unit number estimatebased rates of progression of ALS predict patient survival Muscle Nerve 1999 22 1571 5 10514236
  48. [52]deCarvalho M Scotto M Lopes A Swash M Quantitating progression in ALS Neurology 2005 64 1783 5 15911812
  49. [55]Ince PG Lowe J Shaw PJ Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology Neuropathol Appl Neurobiol 1998 24 104 17 9634206
  50. [56]Olney RK Murphy J Forshew D Garwood E Miller BL Langmore S The effects of executive and behavioural dysfunction on the course of ALS Neurology 2005 65 1774 7 16344521
  51. [57]Lomen-Hoerth C Murphy J Langmore S Kramer JH Olney RK Miller B Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003 60 1094 7 12682312
  52. [58]Rippon GA Scarmeas N Gordon PH Murphy PL Albert SM Mitsumoto H An observational study of cognitive impairment in amyotrophic lateral sclerosis Arch Neurol 2006 63 345 52 16533961
  53. [59]Desport JC Preux PM Truong TC Vallat JM Sautereau D Couratier P Nutritional status is a prognostic factor for survival in ALS patients Neurology 1999 53 1059 63 10496266
  54. [60]Ringel SP Murphy JR Alderson MK Bryan W England JD Miller RG The natural history of amyotrophic lateral sclerosis Neurology 1993 43 1316 22 8327132
  55. [61]Czaplinsli A Yen AA Appel SH Forced vital capacity (FCV) as an indicator of survival and disease progression in an ALS clinic population J Neurol Neurosurg Psychiatry 2006 77 390 2 16484652 PMC2077717
  56. [62]Schiffman PL Belsh JM Pulmonary function at diagnosis of ALS: rate of deterioration Chest 1993 103 508 13 8432145
  57. [63]Lyall RA Donaldson N Polkey MI Leigh PN Moxham J Respiratory muscle strength and ventilatory failure in ALS Brain 2001 124 200 13 11571218
  58. [64]Schmid EP Drachman DB Wiener CM Clawson L Kimball L Lechtzin N Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design Muscle Nerve 2006 33 127 32 16258948
  59. [65]Jablecki CK Berry C Leach J Survival prediction in amyotrophic lateral sclerosis Muscle Nerve 1989 12 833 41 2608080
  60. [66]Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial clinical limits of amyotrophic lateral sclerosis workshop contributors El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis J Neurol Sci 1994 124 Suppl 96 107 7807156
  61. [67]Turner MR Parton MJ Shaw CE Leigh PN Al-Chalabi A Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990 2002 J Neurol Neurosurg Psychiatry 2003 74 995 7 12810805 PMC1738535
  62. [68]Traynor BJ Alexander M Corr B Frost E Hardiman O An outcome study of riluzole in amyotrophic lateral sclerosis. A population-based study in Ireland, 1996 2000 J Neurol 2003 250 473 9 12700914
  63. [69]Mitchell JD O’Brien MR Joshi M Audit of outcomes in motor neuron disease (MND) patients treated with riluzole Amyotroph Lateral Scler Other Motor Neuron Disord 2006 7 67 77 16753969
  64. [70]Miller RG Mitchell JD Lyon M Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev 1 2007 24 1 D001447 17253460
  65. [71]Mathus-Vliegen LMH Louwersee LS Merkus MP Tytgat GNJ de Jong JMBV Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function Gastrointest Endosc 1994 40 463 9 7926537
  66. [72]Chiò A Finocchiaro E Meineri P Bottacchi E Schiffer D the ALS Percutaneous Endoscopic Gastrostomy Study Group Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS Neurology 1999 53 1123 5 10496278
  67. [73]Forbes RB Colville S Swingler RJ Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neuron disease. A record linkage study from the Scottish Motor Neurone Disease Register J Neurol 2004 251 813 7 15258782
  68. [74]Heffernan C Jenkinson C Holmes T Feder G Kupfer R Leigh PN Nutritional management in MND/ALS patients: an evidence based review Amyotroph Lateral Scler Other Motor Neuron Dis 2004 5 72 83 15204009
  69. [75]Pinto AC Evangelista T Carvalho M Alves MA Sales Luis ML Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial J Neurol Sci 1995 129 Suppl 19 26 7595610
  70. [76]Pinto A deCarvalho M Evangelista T Lopes A Sales-Lu ís L Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients Amyotroph Lateral Scler Other Motor Neuron Disord 2003 4 31 5 12745616
  71. [77]Traynor BJ Alexander M Corr B Frost E Hardiman O Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996 2000 J Neurol Neurosurg Psychiatr 2003 74 1258 61 12933930 PMC1738639
  72. [78]Chiò A Bottacchi E Buffa C Mutani R Mora G PARALS Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities J Neurol Neurosurg Psychiatry 2006 77 948 50 16614011 PMC2077622
  73. [79]Zoccolella S Beghi E Palagano G Fraddosio A Guerra V Lepore V ALS multidisciplinary clinic and survival: results from a population-based study in southern Italy J Neurol 2007 254 1107 12 17431705
  74. [80]Siddique T Pericak-Vance MA Caliendo J Hong ST Hung WY Kaplan J Lack of association between apolipoprotein E genotype and amyotrophic lateral sclerosis Neurogenetics 1998 1 213 6 10737125
  75. [81]Lacomblez L Doppler V Beucler I Costes G Salachas F Raisonner A APOE: a potential marker of disease progression in ALS Neurology 2002 58 1112 4 11940705
  76. [82]Veldink JH van den Berg LH Cobben JM Stulp RP de Jong JMBV Vogels OJ Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS Neurology 2001 56 753 7 11274309
  77. [83]Gamez J Barcelo MJ Munoz X Xarmona F Cusco I Baiget M Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients Neurology 2002 59 1456 60 12427907
  78. [84]Jokic N Gonzalez de Aguilar JL Pradat PF Dupuis L Echaniz-Laguna A Muller A Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity Ann Neurol 2005 57 553 6 15786457
  79. [85]Dupuis L Corcia P Fergani A Gonzalez de Aguilar JL Bonnefont-Rousselot D Bittar R Dyslipidaemia is a protective factor in amyotrophic lateral sclerosis Neurology 2008 70 1004 9 18199832
  80. [86]Kalra S Vitale A Cashman NR Genge A Arnold DL Cerebral degeneration predicts survival in amyotrophic lateral sclerosis J Neurol Neurosurg Psychiatry 2006 77 1253 5 16835288 PMC2077382
  81. [87]Zoccolella S Beghi E Palagano G Fraddosio A Samarelli V Lamberti P for the SLAP registry Predictors of delay in the diagnosis and clinical entry of amyotrophic lateral sclerosis patients: a population based study J Neurol Sci 2006 250 45 9 16920152
  82. [88]de Carvalho M Scotto M Lopes A Swash M Quantitating progression in ALS Neurology 2005 64 1783 5 15911812
  83. [89]Pradas J Finison L Andres PL Thornell B Hollander D Munsat TL The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials Neurology 1993 43 751 5 8469335
  84. [90]Altman DG Bland JM Treatment allocation by minimization Br Med J 2005 330 853 15817555 PMC556084
  85. [91]Treasure T MacRae KD Minimization: the platinum standard for trials Br Med J 1998 317 363 PMC1113668 9694748
  86. [92]Schwid RS Cutter GR Futility studies: spending a little to save a lot Neurology 2006 66 626 7 16534098
  87. [93]Levy G Kaufmann P Buchsbaum R Montes J Barsdorf A Arbing R A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS Neurology 2006 66 660 3 16534103
  88. [94]Rosen AD Amyotrophic lateral sclerosis: clinical features and prognosis Arch Neurol 1978 35 638 42 697604
  89. [96]Chiò A Brignolio F Leone M Mortara P Rosso MG Tribolo A Schiffer D A survival analysis of 155 cases of progressive muscular atrophy Acta Neurol Scand 1985 72 407 13 4082906
  90. [97]Gubbay SS Kahana E Zilber N Cooper G Pintov S Leibowitz Y Amyotrophic lateral sclerosis: a study of its presentation and prognosis J Neurol 1985 232 295 300 4056836
  91. [98]Chiò A Brignolio F Meineri P Schiffer D Phenotypic and genotypic heterogeneity of dominantly inherited amyotrophic lateral sclerosis Acta Neurol Scand 1987 75 277 82 3591277
  92. [99]Eisen A Schulzer M MacNeil M Pant B Mak E Duration of amyotrophic lateral sclerosis is age dependent Muscle Nerve 1993 16 27 32 8423829
  93. [100]Mandrioli J Faglioni P Nichelli P Sola P Amyotrophic lateral sclerosis: prognostic indicators of survival Amyotroph Lateral Scler 2006 7 211 20 17127559
  94. [101]Czaplinski A Yen AA Simpson EP Appel SH Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006 63 1139 43 16908741
  95. [102]Kristensen O Melgaard B Motor neuron disease: prognosis and epidemiology Acta Neurol Scand 1977 56 299 308 920110
  96. [103]Forsgren L Almay BG Holmgren G Wall S Epidemiology of motor neuron disease in northern Sweden Acta Neurol Scand 1983 68 20 9 6604389
  97. [104]Mortara P Chiò A Rosso MG Leone M Schiffer D Motor neuron disease in the province of Turin, Italy, 1966 1980. Survival analysis in an unselected population J Neurol Sci 1984 66 165 73 6530610
  98. [105]Granieri E Carreras M Tola R Paolino E Tralli G Eleopra R Serra G Motor neuron disease in the province of Ferrara, Italy, 1964 1982 Neurology 1988 38 1604 8 3419606
  99. [106]Bettoni L Bazzani M Bortone E Descola I Pisani E Mancia D Steadiness of amyotrophic lateral sclerosis in the province of Parma, Italy, 1960 1990 Acta Neurol Scand 1994 90 276 80 7839815
  100. [107]Alcaz S Jarebinski M Pekmezovic T Stevic-Marinkovic Z Pavlovic S Apolstoski S Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia Acta Neurol Scand 1996 94 264 8 8937538
  101. [108]Argyriou AA Polychromatopoulos P Papapetropolous S Ellul J Andriopoulos I Katsoulas G Clinical and epidemiological features of motor neuron disease in southwestern Greece Acta Neurol Scand 2005 111 108 13 15644070

Cited by

Sorted by citations

Authors
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium
Affiliations
  • Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
  • Harvard University (US)
  • Trinity College Dublin (IE)
  • Ninewells Hospital (GB)
  • Royal Preston Hospital (GB)
  • Mario Negri Institute for Pharmacological Research (IT)
Corresponding author
Chiò, Adriano
ORCID
Venue
Amyotrophic Lateral Sclerosis
Publisher
Informa UK Limited
Published
2009-01
Volume
10
Issue
5-6
Pages
310-323
ISSN
  • 1471-180X (ISSN-L)
  • 1748-2968
DOI
10.3109/17482960802566824
PMC
PMC3515205
OpenAlex
W2155221045
Cited by
1,172
References
3
Citations by year
2026: 76 · 2025: 88 · 2024: 99 · 2023: 111 · 2022: 98 · 2021: 90 · 2020: 96 · 2019: 76 · 2018: 79 · 2017: 71 · 2016: 67 · 2015: 52 · 2014: 48 · 2013: 23 · 2012: 35
FWCI
3.53
Type
journal article
Language
en
Open access
Locations
  • Amyotrophic Lateral Sclerosis (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (ZIAAG000933)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Genetics › Neurogenetic and Muscular Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
Keywords
prognostic factors, survival, bulbar onset, age, symptom progression, frontotemporal dementia, nutritional status, respiratory function, enteral nutrition, noninvasive positive pressure ventilation, biomarkers, clinical trial design, randomization, minimization method, futility
MeSH terms
Amyotrophic Lateral Sclerosis, Clinical Trials as Topic, Humans, Nutritional Status, Prognosis, Prospective Studies, Respiration, Retrospective Studies, Severity of Illness Index, Biomarkers, Survival Rate, Age of Onset, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review